Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

ribociclib 1palbociclib 1abemaciclib 1AZD9833 1AZD9496 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ER+ HER2- Advanced Breast Cancer × Clear all
NCT06188520 2026-05-11

CYCAD-1

AstraZeneca

Phase 1/2 Recruiting
564 enrolled
BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT03596658 2022-09-01

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
4 enrolled
Breast

ER+ HER2- Advanced Breast Cancer

NCT02248090 2019-06-24

AZD9496 First Time in Patients Ascending Dose Study

AstraZeneca

Phase 1 Completed
45 enrolled
Breast

ER+ HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡